Responsabile dell'U.O.
Cognome e Nome
DE PETRO GIUSEPPINA
Qualifica
PO
Dipartimento
Dept of Molecular and Translational Medicine (DMMT)
Settore scientifico disciplinare
BIOLOGIA APPLICATA BIO/13
giuseppina.depetro@unibs.it
Telefono
3457229513
Personale strutturato
Cognome e Nome
Salvi Alessandro
Qualifica
PA
Dipartimento
Dept of Molecular and Translational Medicine (DMMT)
Ente di appartenenza
Università di Brescia
Cognome e Nome
Schiavone Marco
Qualifica
PA
Dipartimento
Dept of Molecular and Translational Medicine (DMMT)
Ente di appartenenza
Università di Brescia
Cognome e Nome
Piovani Giovanna
Qualifica
Ricercatore
Dipartimento
Dept of Molecular and Translational Medicine (DMMT)
Ente di appartenenza
Università di Brescia
Personale non strutturato
Cognome e Nome
Grossi Ilaria
Qualifica
Assegnista
Dipartimento
Dept of Molecular and Translational Medicine (DMMT)
Ente di appartenenza
Università di Brescia
Cognome e Nome
Ferraro Rosalba
Qualifica
Assegnista
Dipartimento
Dept of Molecular and Translational Medicine (DMMT)
Ente di appartenenza
Università di Brescia
Cognome e Nome
Cannone Elena
Qualifica
Ph.D student
Dipartimento
Dept of Molecular and Translational Medicine (DMMT)
Ente di appartenenza
Università di Brescia
Cognome e Nome
Pelisenko Iulia Andreea
Qualifica
Ph.D student
Dipartimento
Dept of Molecular and Translational Medicine (DMMT)
Ente di appartenenza
Università di Brescia
Linee di ricerca
The scientific activity of the Research Unit (RU) is focused on cellular and molecular studies to understand the molecular basis of given human diseases with the aim to develop biomarkers with prognostic or diagnostic value and to design innovative therapies in this era of precision medicine.
Prof. De Petro and Prof. Salvi are studying epigenetic mechanisms of gene expression regulation mediated by DNA methylation and by non coding RNAs (microRNAs and Long-ncRNAs) in human solid tumors, Hepatocellular Carcinoma (HCC), Head and Neck squamous cell carcinoma (HNSCC) and Breast Cancer. The research lines are:
- Development of an innovative methylation specific-droplet digital PCR (MS-ddPCR) assay to quantify the methylation of two tumour suppressor genes (SEPT9 and SHOX2) using circulating cell-free DNA from plasma of patients with HNSCC with the aim to quickly detect possible cancer recurrence.
-Multicentric study for the validation of microRNA-23b-3p, -193a3p,-126a-3p, of lncRNA TERRA and TERC and of TERTmRNA as tissutal and/or ciculating biomarkers of HCC with prognostic or diagnostic value by innovative ddPCR determinations of the transcript expression; the data will allow the molecular stratification of HCC patients.
- Development of Extracellular Vesicles (EV) enriched of tumour suppressor ncRNAs (lncRNAs and miRs) for an innovative therapy of breast cancer that will be tested on breast cancer xenograft in zebrafish.
Prof. Schiavone is pursuing these research lines: -Identification of new druggable targets for Duchenne Muscular Dystrophy (DMD) using zebrafish models and patient cells. - Towards a new effective therapy for myopathies based on different cocktails with mitochondrial PTP inhibitors (zebrafish models, mouse models and patient cells). -Dissecting mechanisms involved in the early stages of both DMD and Myofibrillar Myopathies (zebrafish models and patient biopsies). - Functional study of different genes in zebrafish development.
Dr. Piovani is focused on the cellular and molecular basis of developmental disorders, on chromosal syndromes. She is pursuing the -study of patient-specific iPSC from subjects with Cri-du Chat syndrome, characterized by a deletion in the arm p of chromosome 5, to deeply understand the molecular basis of this syndrome.
Tecnologie in uso dall'UO
- We have applied the ddPCR to quantify methylated DNA and the expression levels of transcripts, mRNAs, microRNAs and Long ncRNAs: -We have developed an innovative methylation specific-droplet digital PCR (MS-ddPCR) assay to determine the absolute amount of circulating cell free DNA of some tumour suppressor genes in plasma of cancer patients. -We have developed specific ddPCR assay to determine the absolute quantification of expression variation of circulating / extracellular ncRNAs in cancer cell lines and in their EVs and in plasma of cancer patients. We have used qPCR array to study differentpanels of ncRNAs in cancer cell lines treated with anticancer drugs.
- For DNA methylation studies we have used the Me-Dip-chip technology, the methylated DNA immunoprecipitation coupled with Affymetrix Human Promoter 1.0R Tiling Arrays. For the validation of DNA-Methylation data we have used COBRA assay and direct bisulfite sequencing . For the study of methylation CpG sites associated with miRs we have developd innovative methylation specific PCR (MSP) assay.
- The zebrafish model is mainly used for functional study of genes, for the identification of new druggable targets of given diseases, to test the therapeutic effects of novel molecules and of EV enriched of ncRNAs on various diseases, genetic diseases and cancer diseases.
- The iPSC technology is used to generate patient-specific iPSCs from subjects affected by crhomosomal syndromes and to study the induced differentiated cells, mainly neurons.
Strumentazione
Denominazione
Droplet Digital PCR Droplet (QX200, Bio-Rad)
5 thermocyclers
Affymetrix GeneChip platform
For NGS studies Ion GeneStudio S5 platform (Thermofisher)
Zebrafish Facility hosts almost 1500 animals
Struttura ove la strumentazione è allocata
(DMMT), Division of Biology and Genetics
(DMMT), Division of Biology and Genetics
(DMMT), Division of Biology and Genetics
(DMMT), Division of Biology and Genetics
(DMMT)
Responsabile
Prof. Alessandro Salvi
Prof. Marina Colombi
Prof. Marina Colombi
Prof. Massimo Gennarelli
Proff. Marco Schiavone; Marco Presta
Pubblicazioni
- Lasp1 Expression Is Implicated in Embryonic Development of Zebrafish. Grossi I, Schiavone M, Cannone E, Grejdan OA, Tobia C, Bonomini F, Rezzani R, Salvi A, De Petro G. Genes (Basel). 2022 Dec 22;14(1):35. doi: 10.3390/genes14010035. PMID: 36672776
- Expression of Cellular and Extracellular TERRA, TERC and TERT in Hepatocellular Carcinoma. Manganelli M, Grossi I, Corsi J, D'Agostino VG, Jurikova K, Cusanelli E, Molfino S, Portolani N, Salvi A, De Petro G.Int J Mol Sci. 2022 May 31;23(11):6183. doi: 10.3390/ijms23116183.PMID: 35682861
- Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib. Manganelli M, Grossi I, Ferracin M, Guerriero P, Negrini M, Ghidini M, Senti C, Ratti M, Pizzo C, Passalacqua R, Molfino S, Baiocchi G, Portolani N, Marchina E, De Petro G, Salvi A. Biomedicines. 2021 Jul 13;9(7):813. doi: 10.3390/biomedicines9070813.PMID: 34356875
- DNA methylation variations in familial female and male breast cancer. Abeni E, Grossi I, Marchina E, Coniglio A, Incardona P, Cavalli P, Zorzi F, Chiodera PL, Paties CT, Crosatti M, De Petro G, Salvi A. Oncol Lett. 2021 Jun;21(6):468. doi: 10.3892/ol.2021.12729. Epub 2021 Apr 12. PMID: 33907578
- MicroRNA‑34a‑5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study. Grossi I, Radeghieri A, Paolini L, Porrini V, Pilotto A, Padovani A, Marengoni A, Barbon A, Bellucci A, Pizzi M, Salvi A, De Petro G. Int J Mol Med. 2021 Feb;47(2):533-546. doi: 10.3892/ijmm.2020.4806. PMID: 33416118
- Differential expression profiling of long non-coding RNA GAS5 and miR-126-3p in human cancer cells in response to sorafenib. Faranda T, Grossi I, Manganelli M, Marchina E, Baiocchi G, Portolani N, Crosatti M, De Petro G, Salvi A. Sci Rep. 2019 Jun 24;9(1):9118. doi: 10.1038/s41598-019-45604-2. PMID: 31235746
- Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells. Abeni E, Salvi A, Marchina E, Traversa M, Arici B, De Petro G.Int J Oncol. 2017 Jul;51(1):128-144. doi: 10.3892/ijo.2017.4019. PMID: 28560380
- Analysis of a nanoparticle‑enriched fraction of plasma reveals miRNA candidates for Down syndrome pathogenesis. Salvi A, Vezzoli M, Busatto S, Paolini L, Faranda T, Abeni E, Caracausi M, Antonaros F, Piovesan A, Locatelli C, Cocchi G, Alvisi G, De Petro G, Ricotta D, Bergese P, Radeghieri A. Int J Mol Med. 2019 Jun;43(6):2303-2318. doi: 10.3892/ijmm.2019.4158. Epub 2019 Apr 9.PMID: 31017260
- Treatment with a triazole inhibitor of the mitochondrial permeability transition pore fully corrects the pathology of sapje zebrafish lacking dystrophin Stocco, A. , Smolina, N., Sabatelli, P.,Schiavone, M., Bernardi, P.Pharmacological Research, 2021, 165, 105421
- Generation of induced pluripotent stem cells (iPSCs) from patient with Cri du Chat Syndrome.Piovani G, Lanzi G, Ferraro RM, Masneri S, Barisani C, Savio G, Giliani SC.Stem Cell Res. 2019 Mar;35:101393. doi: 10.1016/j.scr.2019.101393 PMID: 30711802
Dottorati di ricerca
Componente UO
De Petro Giuseppina
Salvi Alessandro
Schiavone Marco
Piovani Giovanna
Dottorato di ricerca
Gen. Molecolare, Biotec. e Med. sper.
Precision Medicine
Precision Medicine
Genetica Molecolare, Biotecnologie e Medicina sperimentale
Coordinatore
Prof.Eugenio Monti
Prof. Marco Presta
Prof. Marco Presta
Prof.Eugenio Monti
Sede
DMMT
DMMT
DMMT
DMMT